Hutchens & Kramer Investment Management Group LLC Increases Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Hutchens & Kramer Investment Management Group LLC lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 27.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,135 shares of the life sciences company’s stock after buying an additional 676 shares during the quarter. Hutchens & Kramer Investment Management Group LLC’s holdings in Illumina were worth $404,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ILMN. Trivant Custom Portfolio Group LLC increased its position in Illumina by 166.7% during the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after buying an additional 125 shares in the last quarter. Versant Capital Management Inc increased its position in Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 246 shares in the last quarter. Industrial Alliance Investment Management Inc. acquired a new position in Illumina in the 2nd quarter valued at about $34,000. Massmutual Trust Co. FSB ADV lifted its holdings in Illumina by 86.8% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after purchasing an additional 132 shares in the last quarter. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of Illumina during the 2nd quarter worth about $61,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Down 1.0 %

Illumina stock traded down $1.46 during midday trading on Tuesday, hitting $147.61. 2,342,295 shares of the company were exchanged, compared to its average volume of 2,032,849. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $151.40. The company’s fifty day moving average price is $130.87 and its 200-day moving average price is $120.72. The company has a market cap of $23.51 billion, a PE ratio of -18.17 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the firm earned $0.32 earnings per share. The business’s quarterly revenue was down 5.4% compared to the same quarter last year. On average, research analysts predict that Illumina, Inc. will post 3.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent analyst reports. Scotiabank reduced their price objective on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research note on Thursday, August 15th. Royal Bank of Canada reissued an “outperform” rating and set a $252.00 price target on shares of Illumina in a research note on Thursday, October 10th. JPMorgan Chase & Co. lowered their price objective on Illumina from $130.00 to $125.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Piper Sandler dropped their target price on Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Finally, Citigroup raised their price target on Illumina from $140.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Illumina currently has an average rating of “Moderate Buy” and a consensus price target of $150.58.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.